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Rotavirus is the leading cause of severe diarrheal disease and dehydration in infants in both developed and
developing countries. Vaccines have recently been developed, but detailed epidemiological information,
which is needed for decisions about how and where to introduce vaccination, was lacking for many Latin
American countries. The primary objective of this study was to measure the incidence and disease burden
of rotavirus in young children presenting to Latin American hospitals with gastroenteritis. In addition it
allowed to setting up the methodology to further conduct a large phase III trial with a rotavirus vaccine
in the region. This was a prospective, multi-center surveillance study of gastroenteritis in children <3 years
old presenting to hospitals in 11 LatinAmerican countries. Questionnaires and stool sampleswere collected
from 6521 of 8031 enrolled cases (73% inpatients). Among these, 3122 (49%)were rotavirus positive. Of the
rotavirus-positive cases, 12% were <6 months, 48% <1 year and 87% <2 years old; 23% received antibiotics
before diagnosis. Median hospital stay was 2 days, 78% received intravenous rehydration. Overall strain
distribution was G1 (59%), G2 (1%), G3 (12%), G4 (20%), G9 (6%), G12 (1%), untypable (7%) with large local
variations. The direct economic impact on families was considerable: 48% of caregivers lost time from paid
work and 69% of families were ﬁnancially affected by their child’s illness. This study conﬁrms the high
disease burden of rotavirus gastroenteritis among children in Latin America, which might be reduced by
the use of effective vaccines.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.Chagas, Secretaria de Vigilância e
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Rotavirus causes a considerable disease burden worldwide.
Each year, rotavirus is estimated to be responsible for over 130
million cases of diarrhea, requiring 25 million clinic visits and 2
million hospitalizations [1] and causing nearly 600,000 deaths in
children under 5 years of age [2]. Although the incidence of rotavi-
rus appears similar throughout the world, a disproportionate num-
ber of deaths occur in developing countries. Parashar et al. [1,2]
have estimated that 82% of rotavirus deaths occur in children in
the poorest countries.
The World Health Organization (WHO) has identiﬁed rotavirus
as ‘the leading cause of severe diarrheal disease and dehydration of
infants in both developed and developing countries [3].
Detailed, prospective information on the burden of disease
caused by rotavirus infection was lacking for many Latin American
countries [1]. However, such information is essential to take
decisions about whether and how to introduce vaccination [4]. In
accordance with WHO recommendations [3], this study was
conducted to describe the epidemiology and disease burden of
rotavirus in children under 3 years of age in various countries
throughout Latin America. In addition to this, it was an opportunity
of setting up the ﬁeld and laboratory methodologies to subse-
quently conduct a large phase III trial with the human rotavirus
vaccine in Latin America.2. Material and methods
This was a multi-country, multi-center, prospective, hospital-
based study which took place in 75 centers spread over 11 Latin
American countries: Argentina, Brazil, Chile, Colombia, Costa Rica,
Dominican Republic, Honduras, Mexico, Nicaragua, Panama, and
Venezuela. Centers were selected by their capacity to perform sur-
veillance for acute gastroenteritis and their potential to further
participate in a large safety and efﬁcacy trial of RIX4414 vaccine
(Rotarix™, GlaxoSmithKline [GSK] Biologicals, Rixensart, Belgium).
The surveillance ran from November 2002 to September 2003, un-
til the start of the trial, and was regarded as an opportunity to
establish all logistic and laboratory methodologies required to con-
duct a subsequent large phase III trial with the RIX4414 vaccine.
We aimed to enroll all children less than 3 years of age treated at
participating hospitals for an episode of acute gastroenteritis.
Acute gastroenteritis was deﬁned as diarrhea (three or more looser
stools within a day), with or without vomiting. Severe gastroenter-
itis was deﬁned as hospitalization (at least over one night) with re-
hydration therapy (oral or intravenous (IV), equivalent to WHO
plan B or C) at a medical facility for gastroenteritis.
After giving informed consent, parents, or guardians were asked
or assisted to complete a questionnaire about the current episode
of gastroenteritis, such as whether the child received oral or intra-
venous rehydration or antibiotics, and about the length of hospital-
ization. Additional treatment details were obtained from medical
charts.
A questionnaire was used to collect details about socioeconomic
impact for caregivers including: taking time off work; distance
traveled to the hospital; cost of reaching the hospital; cost of med-
ication, clinical tests and other medical fees; and the overall ﬁnan-
cial impact of the illness. The questionnaire was distributed to the
parents of 50 consecutive inpatients and 50 consecutive outpa-
tients per country at centers selected to give a representative sam-
ple across the study population.
Stool samples were collected for each episode, tested for rotavi-
rus antigen, and, if found positive, genotyped. Initial testing was
performed at local centers. Rota-Strip (Coris BioConcept, Gemb-
loux, Belgium) or ELISA (Premier Rotaclone, Medidian DiagnosticsInc., USA) was used to detect rotavirus antigen. Genotyping was
performed using reverse transcriptase polymerase chain reaction
(RT-PCR) techniques [5]. Further genotyping on samples that could
not be characterized by local centers was performed at GSK Biolog-
icals, Rixensart, Belgium.3. Results
The surveillance period lasted from November 2002 to Septem-
ber 2003. Study duration at each center varied between 2 and
8 months, depending on when surveillance started (Table 1).
3.1. Subjects and stool samples
A total of 8031 childrenwith acute gastroenteritis were enrolled,
of whom 73% (5867) were considered inpatients and 27% (2157)
outpatients (hospitalization status was missing in 7 cases). The
number of subjects enrolled by country is summarized in Table 1.
The male:female ratio was 1.4:1. The median age of the subjects
was 1 year. Stool samples were collected from 81% of patients.
Sampling frequency varied by country, ranging from 48% in Brazil
and 59% in Chile, to almost 100% in all other countries. Of the
6361 stool samples tested for rotavirus, 49% (3122) tested positive.
The proportion of rotavirus-positive samples showed seasonal var-
iation, with country-speciﬁc values ranging from 4% to 79% of cases
each month. Of the rotavirus-positive cases, 12% (379) were under
6 months old, 35% (1107) were between 6 and 11 months old, 40%
(1239) were between 12 and 23 months old, and 13% (397) were
between 24 and 35 months old. The age distribution varied be-
tween countries. In Venezuela, for example, a higher proportion
of rotavirus infections occurred in very young children (11% of cases
were less than 3 months of age compared with 1.5% or less in other
countries in this study). The proportion of children aged less than
7 months was highest in Venezuela and the Dominican Republic
(30% and 28%, respectively compared with 6–18% in other coun-
tries). In Colombia, children were only enrolled from 6 months of
age. Fig. 1 shows the proportion of cases at different ages by country
and overall.
3.2. Genotypes
Genotype data were available from 1236 samples. Overall, 59
(5%) had mixed genotypes, with relatively high rates in Mexico
(15%) and Nicaragua (21%). A total of 7% of samples were untypa-
ble. Table 2 shows strain distribution by country. The most com-
mon strain was G1 (59% overall) except in Chile, where G4
predominated, and in Costa Rica and Nicaragua where G3 predom-
inated. G9 was as high as 22% of cases in Brazil and 14% in Mexico.
G12 was found occasionally in Brazil, Mexico, and the Dominican
Republic. A total of 15 strains (11%) from the Dominican Republic
were of non-human origin.
3.3. Treatments and outcomes
Before coming to the hospital, 5% of children (390) received IV
rehydration, 46% (3657) received oral rehydration, and 23%
(1815) received antibiotics. At the hospital, 78% (6263) received
IV rehydration, 63% (5028) received oral rehydration, and 30%
(2415) received antibiotics. The proportions receiving these treat-
ments were similar for rotavirus-positive and rotavirus-negative
cases. Median duration of hospitalization was 2 days for both rota-
virus-positive and negative cases. However, national medians ran-
ged from 0 (in the Dominican Republic) to 4 days (in Brazil). Two
fatalities occurred among the 2290 children with RV for whom
the outcome was known.
Table 1
Study duration, enrollment and range of monthly percentages of rotavirus-positive stool samples by country.
Study start Study end Study duration
(days)
Children
enrolled
N (samples
tested)
% Rotavirus positive stool samples
Overall Maximum
monthly
Minimum
monthly
Argentina March 2003 July 2003 150 639 580 50 55 43
Brazil March 2003 September
2003
194 1475 680 46 58 38
Chile January 2003 June 2003 158 886 525 51 60 35
Colombia May 2003 June 2003 50 55 46 17 24 14
Costa Rica December
2002
June 2003 190 795 635 53 63 11
Dominican
Rep.
January 2003 June 2003 153 400 395 62 80 35
Honduras January 2003 June 2003 151 405 394 37 52 9
Mexico January 2003 June 2003 179 1306 1154 59 79 10
Nicaragua March 2003 June 2003 114 229 219 61 70 51
Panama January 2003 June 2003 161 1491 1432 41 67 4
Venezuela November
2002
June 2003 220 350 301 40 78 8
Overall November
2002
September
2003
315 8031 6361 49 55 27
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The cost questionnaire was completed by 675 caregivers (96% of
whom were the child’s parents) looking after children with rotavi-
rus-positive disease. The median distance to bring the child to hos-
pital was 8 km (but ranged from 0.1 to 148 km); 71% of relatives
had to pay for this transport and 58% had to pay for transport to
visit their child. The median number of trips to the hospital to visit
their child was three (ranging from 1 to 24). The most common
modes of transport were buses or trains (used for 33% of all jour-
neys), then taxis (28%) or cars (25%).
Nearly half the caregivers (46%) paid for medication, 14% paid
for clinical tests, 34% for consultation, and 45% for other fees. The
proportion of families paying for each aspect varied considerably
by country. Of those completing the questionnaire, 48% (320) had
lost time from paid work, with a median of 12 h (range 1–108) lost.
Most families (69%) stated that they had been ﬁnancially affected
by their child’s illness. Families paid for medical expenses by bor-
rowing in 52% of cases, while 31% said they had to cut other ex-
penses, 29% used savings, 11% asked for donations, and 3% sold
assets.Fig. 1. Cumulative age distribution (%) of rotavirus-positive subjects by country and
over all countries. This ﬁgure shows the proportion of cases at different ages by
country and overall.4. Discussion
This multi-country, prospective, hospital-based study of 8031
children represents the largest epidemiological study of rotavirus
gastroenteritis in Latin America to date. It conﬁrms the consider-
able disease burden associated with rotavirus infection in children
less than 3 years of age.
Rotavirus was identiﬁed from almost half the children (49%)
who received treatment at a hospital for acute gastroenteritis. This
ﬁnding is similar to that reported previously [6], where rotavirus
was found in 47% of children under 36 months hospitalized with
diarrhea during a period of 2 years in Chile, 38% in Venezuela,
and 71% in Argentina. In a 5-year study in Venezuela, rotavirus
was observed in 43% of inpatient cases [7]. In another 5-year Ven-
ezuelan study, rotavirus accounted for 31% of gastroenteritis hospi-
talizations [8]. A review of 18 studies across Latin America
reported a median rate of rotavirus of 31% in both inpatients and
outpatients [4].
Although rotavirus infection shows a seasonal pattern, it has
been shown to occur all year round [7,9]. Kane et al. [4] noted that
‘in most countries, rotavirus was detected throughout the year’ and
found only two locations in Brazil where rotavirus was not de-
tected for two consecutive months. Velázquez et al. [10] showed
a peak in mortality in childhood diarrhea during the fall-winter
season in Mexico which coincided with a higher proportion of rota-
virus-positive cases. In our study, rotavirus accounted for about
10% of cases of gastroenteritis in the months when it was least pre-
valent and up to 80% in the high season.
The majority of cases of rotavirus gastroenteritis (87%) occurred
in children under 2 years of age. About half of the cases (48%) oc-
curred under 1 year of age, ranging from 31% in Chile to 71% in
Venezuela. This matches ﬁndings from earlier studies in the region.
Kane et al. [4] found that between 40% and 50% of cases occur be-
fore the age of 1 year in Argentina, Brazil and Paraguay. Similarly to
our ﬁndings, one Venezuelan study in Caracas found a high propor-
tion (85%) of patients with rotavirus gastroenteritis presenting to a
hospital to be under 1 year of age [7]. A study from Valencia in
Venezuela also found that children aged 3–11 months had the
highest frequency of rotavirus infection and more serious disease
than those aged 2–5 years [8]. In this study, the proportion of chil-
dren under 12 months was lower in Valencia than Caracas (61% vs.
85%). In some countries, rotavirus infection occurs at a particularly
early age, possibly due to factors such as heavier exposition owing
to high population density, broad strain diversity, and the year-
Table 2
Rotavirus strain distribution: % of subjects with strains of each type.
N samples serotyped G1 G2 G3 G4 G9 G12 Mixed Untypable
Argentina 95 96 0 0 0 0 0 0 4
Brazil 272 68 1 0.4 2 22 2 2 7
Chile 265 23 1 0 73 0 0 6 9
Colombia 8 88 0 0 0 0 0 0 13
Costa Rica 81 30 0 68 2 0 0 0 0
Dominican Rep. 131 57 2 21 0 0 2 2 19a
Honduras 83 100 0 0 0 0 0 0 0
Mexico 78 79 4 6 14 14 1 15 4
Nicaragua 94 45 3 49 24 0 0 21 4
Panama 100 89 4 7 0 0 0 0 0
Venezuela 29 45 0 14 21 0 0 7 28
Overall 1236 59 1 12 20 6 1 5 7
Note: % across strains can be >100% due to mixed infections.
a Including 11% of non-human origin.
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rotavirus infections occur by 6 months of age [11].
Detailed information about the age distribution is crucial for
designing a vaccine and planning an effective vaccination program.
To be effective for Latin America, a rotavirus vaccine must offer
protection before the age of 4 months and last until at least 2 years
of age when the period of highest risk for severe disease and mor-
tality has passed. Encouraging data on the efﬁcacy of a new human
attenuated rotavirus vaccine have recently been published [9]. As
of May 2010, 13 Latin American countries have introduced
Rotarix™ (GlaxoSmithKline, Rixensart, Belgium), into the national
expanded program for immunization. In addition, RotaTeq™
(Merck Vaccines, Whitehouse Station, New Jersey, USA) has been
integrated into the National Immunization Programs of two
countries.
In line with the global distribution of genotypes [10,12,13], and
with an earlier study in Mexico [14], G1 was the most common
strain overall. However, the emergence of G9 as an important geno-
type in Brazil and Mexico is signiﬁcant. This suggestion of an
increasing importance of G9 in Latin America matches the ﬁnding
that the G9 type is emerging in other regions as well [13,15–20].
The proportion of the G2 genotype in our study was low (1%)
[21,22]. This strain had a higher prevalence in the past and ac-
counted for outbreaks a decade ago [13,23,24]. Rodriguez et al.
[14] found the G2 serotype to represent, on average, 16% among
samples collected from 8 Mexican centers between 1994 and
1997. However, a low prevalence of G2 was also found in a recent
study in Colombia which found serotypes G1, G3 and G9 represent-
ing 57.9%, 21.1% and 15.8% of all typed samples, but G2 comprised
only 5.3% (20). Finally, the preponderance of G3 in Nicaragua and
Costa Rica, as well as G4 in Chile, suggest the presence of local epi-
demics. Equally, G4 has also been described in epidemics in Italy
and Spain [25–27]. Overall, our ﬁndings are suggestive that geno-
type distribution varies largely according to location, even when
data are collected during the same season.
This study also illustrates the substantial economic burden of
rotavirus infection. Most cases presenting to the study centers
were hospitalized (with a median stay of 2 days) and most re-
quired IV rehydration. About one in four children also received
antibiotics, which in most cases were not warranted. The current
study also examined the direct economic effects on affected fami-
lies and showed considerable time taken from work and a marked
ﬁnancial impact on families, about half of whom reported borrow-
ing money to pay medical expenses.
The current study had some limitations. Because, in most of the
countries, surveillance occurred mainly during the expected rota-
virus season, the proportion of cases caused by rotavirus (49%)
may be an overestimate that would mainly reﬂects the diseaseburden during the rotavirus season. However, our ﬁndings are sim-
ilar to those of earlier studies [6,7], suggesting that they may pro-
vide a reasonably accurate picture. As the study did not run for an
entire year, we did not estimate the annual incidence of acute gas-
troenteritis in our study population. Two epidemiological studies
to estimate the incidence of rotavirus-associated hospitalizations
have just been concluded in Argentina and the Dominican Repub-
lic. Those studies lasted for 1 and 2 years respectively and will
therefore provide additional reliable incidence information.
This study exempliﬁes the considerable disease burden associ-
ated with rotavirus infection in Latin America. It conﬁrms the
observation that children between 6 months and 2 years of age
are most commonly affected. As expected, G1 was the most com-
mon serotype responsible for rotavirus infections, although G3,
G4 and especially G9 were also found to be important, varying
by location. Our ﬁndings also indicate that rotavirus infection
poses a considerable socio-economic burden for the families af-
fected. Given the prevalence and disease burden of rotavirus infec-
tion in Latin America, a safe and effective vaccine could provide
important public health beneﬁts.
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